Joshi Alumkal

Associate Professor

  • 2711 Citations
  • 25 h-Index
20022019

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Joshi Alumkal is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 11 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects

  • PACIFIC NORTHWEST PROSTATE CANCER SPORE

    Garzotto, M., Alumkal, J., Higano, C., Hood, L., Lange, P., Plymate, S., Mostaghel, E., Vessella, R. L., Etzioni, R., Gleave, M., Yu, E. Y. -., Stanford, J., Nelson, P. & Etzioni, R.

    National Institutes of Health

    9/19/028/31/18

    Project: Research project

  • Research Output

    BET bromodomain inhibition blocks the function of a critical AR-independent master regulator network in lethal prostate cancer

    Coleman, D. J., Gao, L., King, C. J., Schwartzman, J., Urrutia, J., Sehrawat, A., Tayou, J., Balter, A., Burchard, J., Chiotti, K. E., Derrick, D. S., Sun, D., Xia, Z., Heiser, L. & Alumkal, J., Jan 1 2019, In : Oncogene.

    Research output: Contribution to journalArticle

  • 1 Scopus citations

    Correction: Epigenetic therapy with panobinostat combined with bicalutamide rechallenge in castration-resistant prostate cancer (Clinical Cancer Research (2019) 25 (52-63) DOI: 10.1158/1078-0432.CCR-18-1589)

    Ferrari, A. C., Alumkal, J. J., Stein, M. N., Taplin, M. E., Babb, J., Barnett, E. S., Gomez-Pinillos, A., Liu, X., Moore, D., DiPaola, R. & Beer, T. M., Apr 15 2019, In : Clinical Cancer Research. 25, 8, 1 p.

    Research output: Contribution to journalComment/debate

    Open Access
  • Epigenetic therapy with panobinostat combined with bicalutamide rechallenge in castration-resistant prostate cancer

    Ferrari, A. C., Alumkal, J., Stein, M. N., Taplin, M. E., Babb, J., Barnett, E. S., Gomez-Pinillos, A., Liu, X., Moore, D., DiPaola, R. & Beer, T. T., Jan 1 2019, In : Clinical Cancer Research. 25, 1, p. 52-63 12 p.

    Research output: Contribution to journalArticle

  • 6 Scopus citations

    Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer

    Chen, W. S., Aggarwal, R., Zhang, L., Zhao, S. G., Thomas, G., Beer, T. T., Quigley, D. A., Foye, A., Playdle, D., Huang, J., Lloyd, P., Lu, E., Sun, D., Guan, X., Rettig, M., Gleave, M., Evans, C. P., Youngren, J., True, L., Lara, P. & 8 others, Kothari, V., Xia, Z., Chi, K. N., Reiter, R. E., Maher, C. A., Feng, F. Y., Small, E. J. & Alumkal, J., Jan 1 2019, In : European Urology.

    Research output: Contribution to journalArticle

  • 8 Scopus citations

    Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancer

    Coleman, D. J., Gao, L., Schwartzman, J., Korkola, J., Sampson, D., Derrick, D. S., Urrutia, J., Balter, A., Burchard, J., King, C. J., Chiotti, K. E., Heiser, L. & Alumkal, J., Dec 1 2019, In : Scientific Reports. 9, 1, 3823.

    Research output: Contribution to journalArticle

    Open Access
  • 3 Scopus citations